ライフサイエンスコーパス: comorbidity

1 ction (mean age 46 years, 56% male, 38% with comorbidities).

2 age was 32 years, and all were free of major comorbidity.

3 ve versus registry data assess patient-level comorbidity.

4 epression and its associated cardiometabolic comorbidity.

5 (9.9%) eligible patients were diagnosed with comorbidity.

6 rs, while accounting for clinically observed comorbidity.

7 ocedure, treatment indication, sex, age, and comorbidity.

8 verall, 67.0% (n = 11 033) had an underlying comorbidity.

9 spectively, even after adjusting for age and comorbidity.

10 and after diagnosis and for controls without comorbidity.

11 ical symptoms and, if present, psychological comorbidity.

12 survivor status and risk of developing each comorbidity.

13 t is sensitive to medication status and ADHD comorbidity.

14 to patient demographics, ocular history, and comorbidity.

15 luding tailoring of treatment to account for comorbidities.

16 Frail patients were older and had more comorbidities.

17 thrombosis location, and underlying medical comorbidities.

18 screening may identify previously unnoticed comorbidities.

19 %) and a higher prevalence of cardiovascular comorbidities.

20 ong-term risks of recurrent stroke and other comorbidities.

21 rly patients and those with multiple chronic comorbidities.

22 systemic health (Charlson Index), and ocular comorbidities.

23 The excess risk was not explained by age and comorbidities.

24 r different coding practices for in-hospital comorbidities.

25 ociation class<II and absence of significant comorbidities.

26 heart failure (HF) have multiple coexisting comorbidities.

27 disorder (PTSD) but also other mental health comorbidities.

28 mpare groups based on egg allergy status and comorbidities.

29 had HIV virologic suppression, and 80.8% had comorbidities.

30 to be principally driven by age, gender, and comorbidities.

31 adjusted for demographic characteristics and comorbidities.

32 thin 3 months of treatment from pre-existing comorbidities.

33 Steroids, iNO, and HFOV were associated with comorbidities.

34 ing for age, sex, race, body mass index, and comorbidities.

35 gardless of age, obesity, or other high-risk comorbidities.

36 h, even after adjustment for obesity-related comorbidities.

37 se, lower alcohol use, and a lower burden of comorbidities.

38 0.77-1.19) after adjusting for age, sex, and comorbidities.

39 l blocker withdrawal was hampered by cardiac comorbidities.

40 kin and is associated with numerous systemic comorbidities.

41 fy patients with candidemia and EE and their comorbidities.

42 or 35 or higher with serious obesity-related comorbidities.

43 phenome-wide screening, to identify genetic comorbidities.

44 itating weight loss and resolving associated comorbidities.

45 fy individuals at risk of developing disease comorbidities.

46 rior accuracy to the model based on clinical comorbidities.

47 tions with severe and enduring mental health comorbidities.

48 emained after adjusting for age, gender, and comorbidities.

49 All 6 had psychiatric comorbidities.

50 the patient's individual clinical needs and comorbidities.

51 ignificantly associated with greater odds of comorbidities.

52 ture is crucial to combating obesity and its comorbidities.

53 s could not be explained by age, gender, and comorbidities.

54 ren (N = 670), OAS (2.26 [2.09-2.44]) and AR comorbidity (1.47 [CI 1.39-1.55]) contributed most to pr

55 ed for HFpEF (hazard ratio [HR] per 1 higher comorbidity, 1.19 [95% CI, 1.14-1.25] versus HFrEF (HR,

56 Hypertension was the most common comorbidity (67.6%), and patients with persistent AF had

57 39.7-54.3]), and a higher proportion had >=1 comorbidity (81.6% vs 73.9%).There were 619 events durin

58 066), lower hematocrit (p = 0.084), and more comorbidities according to Society of Thoracic Surgeons

59 The prevalence and relative burden of comorbidities among hospitalized PLHIV is changing over

60 Muscle atrophy and cachexia are common comorbidities among patients suffering from cancer, chro

61 similar for patients with varying high-risk comorbidities and across the range of ASCVD risk scores.

62 determine the association between noncardiac comorbidities and HRQOL in ambulatory patients with adva

63 rtional hazards models adjusted for baseline comorbidities and identified subsequent hospital admissi

64 Older, sicker patients with comorbidities and longer previous symptom duration recov

65 aption of treatments according to individual comorbidities and offer different mechanisms of treatmen

66 Higher comorbidities and prior advance directives were associat

67 Patients with comorbidities and prior history of cardiovascular diseas

68 signs and symptoms and granular measures of comorbidities and severity of illness.

69 kin disease that is associated with multiple comorbidities and substantially diminishes patients' qua

70 r cognitive, psychological, and psychosocial comorbidities and the effect that epilepsy might have on

71 ife-threatening complications due to its own comorbidities and the side effects of its treatment.

72 elomeres on NRM was independent of recipient comorbidities and was observed selectively among patient

73 ted consequences, women had more psychiatric comorbidities and were less likely to be listed due to a

74 ere used to analyze the relationship between comorbidity and 2-year graft survival, patient survival,

75 ith available data, 709 (68%) had at least 1 comorbidity and 509 (49%) had hypertension.

76 Variations in developmental timing, comorbidity and environmental contexts across individual

77 misuse outcomes, accounting for psychiatric comorbidity and familial factors.

78 Standardized definitions of comorbidity and periodic audits are necessary to ensure

79 FMD clinical characteristics, psychiatric comorbidity and symptomatology, and childhood trauma exp

80 HR = 2.3, 95% CI = 1.6-3.4 when more than 1 comorbidity), and nonacquired immune deficiency syndrome

81 the sociodemographic factors above, medical comorbidities, and a hospital random effect were used to

82 n after adjustments for demographic factors, comorbidities, and baseline brachial flow volume, peribr

83 criteria included age, sex, body mass index, comorbidities, and baseline ventilation requirement 48 h

84 having lower income, public insurance, more comorbidities, and being on dialysis decreased the proba

85 sis have been in its pathogenesis, genetics, comorbidities, and biologic treatments.

86 ic distinctiveness between groups, effect of comorbidities, and differential gene expression with pat

87 distribution at the age of 3 years, allergic comorbidities, and disease exacerbation by the trigger f

88 The causative microorganisms, comorbidities, and durations of symptoms were comparable

89 Demographics, insurance type, comorbidities, and encounter data were collected.

90 ntifying genes and pathways shared among the comorbidities, and evaluated current knowledge about the

91 to account for the diversity of etiologies, comorbidities, and factors driving disease progression,

92 This study assessed the demographics, comorbidities, and health care use of adults ages 20 to

93 s in the LRPV PCI group were older, had more comorbidities, and higher prevalence of moderate-severe

94 Given advanced age, comorbidities, and immune dysfunction, chronic lymphocyt

95 lant characteristics, functional parameters, comorbidities, and immunosuppressive therapies.

96 red with those without, were older, had more comorbidities, and lower utilization of guideline-direct

97 t characteristics, such as sex and metabolic comorbidities, and mortality from COVID-19 remains incom

98 led demographic profiles, systemic symptoms, comorbidities, and ocular manifestations were noted.

99 ression analysis adjusting for demographics, comorbidities, and operative approach.

100 ent admitting years, presence of preexisting comorbidities, and repeat ICU admission.

101 elates of non-RTW, adjusting for age, stage, comorbidities, and socioeconomic covariates.

102 wed for demographics, clinical presentation, comorbidities, and surgeries performed.

103 to the severity of clinical presentation, to comorbidities, and to the potential to receive appropria

104 om a lower socioeconomic status, with higher comorbidity, and admitted to rural and small hospitals (

105 ; P=0.0005) after controlling for sex, race, comorbidity, and cluster.

106 but phenomenological overlap, high rates of comorbidity, and early onset suggest common underlying m

107 es were characterized according to age; sex; comorbidity; antiviral therapy; viral load, expressed as

108 neral population, reporting of OAS and of AR comorbidity appear to be the strongest predictors of pro

109 sing prevalence and incidence of obesity and comorbidities are likely to contribute substantially to

110 Further, sex differences in these comorbidities are substantial.

111 , but the mechanisms underlying the observed comorbidities are unknown.

112 rease, 1.1% [CI, 0.7% to 1.5%]) and physical comorbidity (ARI, 0.9% [CI, 0.1% to 1.7%]).

113 and infantile endogenous endophthalmitis and comorbidities as well as risk factors in the development

114 Comorbidities associated with death (aORs from 2.4 to 3.

115 ression and potential role in the context of comorbidities associated with poor COVID-19 outcomes.

116 ung transcriptome samples from patients with comorbidities associated with severe COVID-19 and found

117 ducted a bioinformatics analysis of COVID-19 comorbidity-associated gene sets, identifying genes and

118 survivors of AYA cancer had multiple (>= 2) comorbidities at 10 years after index date, compared wit

119 iver-related complications and other primary comorbidities at the time of cirrhosis diagnosis.

120 e met ZUMA-1 eligibility criteria because of comorbidities at the time of leukapheresis.

121 sis to estimate the effects of ethnicity and comorbidity at an individual level in the context of reg

122 related risk factors and ocular and systemic comorbidities because they are likely to have severe dis

123 While comorbidity between coronary heart disease (CHD) and dep

124 ogical pathways may explain the considerable comorbidity between depression and cardiometabolic condi

125 Despite the large comorbidity between PTSD and opioid use disorders, as we

126 demiological studies have reported potential comorbidity between the disorders, and movement disturba

127 y ethnicity, when adjusting for age, sex and comorbidities, black patients were at higher odds of dea

128 d this persisted after adjusting for primary comorbidities: body mass index, sex, age, diabetes, and

129 However, older candidates have high comorbidity burden and less physiologic reserve, so the

130 Extra-hepatic comorbidity burden significantly impacts short-term mort

131 Increasing comorbidity burden was associated with a reduction in ge

132 Higher comorbidity burden was significantly associated with hig

133 -Hispanic black, had low income, or had high-comorbidity burden were at higher odds of being in famil

134 ent inflammation mediates the association of comorbidity burden with abnormal cardiac structure/funct

135 HFpEF and are associated with differences in comorbidity burden, HFpEF severity, and fibrosis.

136 % of total costs among those with CKD and no comorbidities but up to 55% among patients with CKD and

137 e the impact of optimization of preoperative comorbidities by nonsurgical clinicians on short-term po

138 is increasing awareness that a wide range of comorbidities can contribute to AF-promoting atrial remo

139 Preoperative comorbidities can have substantial effects on operative

140 After adjusting for age, gender, and comorbidities, chemotherapy in the past 4 weeks had no s

141 imizing pre-clinical models by incorporating comorbidities, co-interventions, and organ support; (3)

142 sis (odds ratio, 2.26; P < .001) and related comorbidities compared with the lowest quintile.

143 A1c), body mass index (BMI), smoking status, comorbidities, consultations, medications, calendar year

144 independent cohort of 117 HFpEF cases and 30 comorbidity controls without heart failure.

145 s between PDR diagnosis and PRP) and medical comorbidities (coronary artery disease and/or myocardial

146 Evidence shows that age-dependent pairs of comorbidities could be a negative prognosis factor for t

147 Earlier diagnosis of these comorbidities could reduce avoidable antibiotic prescrib

148 ata on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness

149 Baseline comorbidities (diabetes, chronic lung disease, previous

150 s registered between 2008-2015 without prior comorbidity diagnoses were eligible for inclusion.

151 After adjustments for demographics, comorbidities, dialysis vintage, and kidney transplantat

152 e interval [CI] 0.33-0.77), although age and comorbidity did not influence this risk.

153 Other comorbidity differences were insignificant (P>0.05).

154 ssions during the study period, the greatest comorbidity disparities between HIV-positive and HIV-neg

155 and HbA1c, less severe TB, and more frequent comorbidities, DM complications, and hypertension (P val

156 These data support comorbidity-driven microvascular inflammation as a patho

157 Comorbidity-driven microvascular inflammation is posited

158 ity during 6 years of follow-up and incident comorbidity during 4 years of follow-up was assessed amo

159 Obesity was the most frequent comorbidity exhibited by coronavirus disease 2019 patien

160 Relevant data, including demographics, comorbidities, extracorporeal membrane oxygenation and c

161 ex, race, AHRQ socioeconomic index, Charlson comorbidity, Framingham stroke risk, Sequential Organ Fa

162 Respondents with DED reported more comorbidities, greater exposure to adverse environmental

163 ll-cause death, independent of demographics, comorbidities, guideline-based surgical triggers, presen

164 the capacity to respond, older patients with comorbidity had larger numbers of activated T cells comp

165 patients in previous S-ICD studies had fewer comorbidities, had less left ventricular dysfunction, an

166 Vascular comorbidities have a deleterious impact on multiple scle

167 gout, novel associations of gout with other comorbidities have been reported, including erectile dys

168 llo-HSCT to older patients and/or those with comorbidities, have led to the use of reduced-intensity

169 ng a larger opioid prescription, having more comorbidities, having a major postoperative complication

170 (hazard ratio, 1.30; p = 0.03), pre-ICU high comorbidity (hazard ratio, 2.28; p < 0.001), pre-ICU phy

171 he offending fungus, site and extent of IMD, comorbidities, hematologic disease prognosis, and future

172 ath (n events = 25 of 77) included number of comorbidities (HR 5.41, P = 0.004), infiltrates (HR 3.08

173 r disease (HR = 1.2, 95% CI = 1.0-1.4 when 1 comorbidity; HR = 2.3, 95% CI = 1.6-3.4 when more than 1

174 rying common PnIST had a lower proportion of comorbidities, hypoxemia, and viral detection and had mo

175 ex, body mass index, mean blood pressure and comorbidity (i.e. hypertension, diabetes and dyslipidemi

176 fections, but it is unclear how the onset of comorbidity impacts antibiotic use.

177 ors are likely to play a role in PNES or its comorbidities in a subset of individuals.

178 ing despite the relatively high incidence of comorbidities in comparison with earlier S-ICD trials.

179 lending further insight into obesity-related comorbidities in humans.

180 ellitus and hypertension are the most common comorbidities in patients with coronavirus infections.

181 ive immunosuppression and high prevalence of comorbidities in patients with ESKD on dialysis raise co

182 tive for managing mental health problems and comorbidities in people exposed to complex trauma.

183 a on population characteristics and critical comorbidities in PWH, particularly across Global Burden

184 ing and proper management of the disease and comorbidities in these patients.

185 in the life expectancy and the incidence of comorbidities in this population.

186 11 uninfected participants of the Copenhagen Comorbidity in HIV Infection (COCOMO) study.

187 Obesity is common comorbidity in patients with schizophrenia.

188 The CCI was 0 (no comorbidities) in 44%, 1-2 in 44% and > 2 (highest decil

189 ing habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments.

190 oxicities induced by chemotherapy, long-term comorbidities including bone loss remain a significant p

191 with both diabetes mellitus and its related comorbidities, including hypertension, obesity, and hear

192 Cardiovascular disease (CVD) and associated comorbidities increase the risk of cognitive impairment

193 fluenced by the dominant effect of age where comorbidities increased with the increasing age of the r

194 ver, the elderly are more fragile because of comorbidities, increased risk of infections and disease-

195 rval [CI]: 3.54 to 12.3; p < 0.01), Charlson Comorbidity Index >5 (HR: 1.53; 95% CI: 1.04 to 2.26; p

196 index was 27.4, 32% demonstrated a Charlson Comorbidity Index >=4.

197 were: age >70 years (P = 0.002), Elixhauser comorbidity index >=8 (P = 0.006), lower gastro-intestin

198 Comorbidity Index (3.8 vs 1.6, p < 0.0005) was higher fo

199 The Charlson comorbidity index (CCI) score was calculated for each pa

200 creasing age, a higher score on the Charlson Comorbidity Index (indicating a greater burden of illnes

201 The primary independent variables were a comorbidity index (sum of 14 noncardiac conditions), a r

202 sum of 14 noncardiac conditions), a residual comorbidity index (without depression), and depression a

203 ion score performs similarly to the Charlson comorbidity index and is associated with polygenic risk

204 ratio, 1.74; 95% CI, 1.63-1.85 for Charlson comorbidity index of 0 vs 2), diagnoses of overdose/pois

205 dian age was 59 years with a mean Elixhauser comorbidity index of 3.1, both increasing over time (P <

206 based on age (>=50 years), an HSCT-specific comorbidity index of more than 2, or both.

207 Charlson Comorbidity Index was 5.1 +/- 1.7 and 14 (7%) were inact

208 smoking habits, baseline Charlson's weighted comorbidity index, and baseline diabetes mellitus.

209 t differ in age, insurance, income, Charlson Comorbidity Index, diabetes or obesity when compared to

210 ithout transfusion-only cases; 2019 maternal comorbidity index.

211 decreasing overall survival with increasing comorbidity index.

212 Region of the world, income, and comorbidities influence adjunctive therapy use and are i

213 raphic information, laboratory data, medical comorbidities, insurance and adherence to cirrhosis qual

214 aortic valve disease and key health-related comorbidities involving the cardiovascular system and au

215 Psychiatric comorbidity is known to impact upon use of nonpsychiatri

216 tain patients' demographics, physical signs, comorbidities, laboratory results, clinical events, and

217 Excluding eyes with comorbidities, logarithm of minimum angle of resolution

218 were younger, had a lower burden of medical comorbidities, lower proportion of squamous cell carcino

219 d-drinking approaches should be promoted and comorbidity management should be strengthened in PWH.

220 The presence of comorbidities may also affect the risk of developing adv

221 for women with depression, although medical comorbidities may dictate a specific type.

222 ntifying ACE2 dysregulation in patients with comorbidities may offer insight as to why COVID-19 sympt

223 r preexisting conditions but not in-hospital comorbidity measures were not significantly different by

224 inase inhibitors (TKIs), a greater number of comorbidities might be the most significant adverse feat

225 n 56 versus 74 years; p<0.001) and had fewer comorbidities, more systemic symptoms and higher lymphoc

226 n baseline demographics, systemic and ocular comorbidities, ocular surgical history, best-corrected v

227 .34-0.39 for age 80-105 vs age 18-39), fewer comorbidities (odds ratio, 1.74; 95% CI, 1.63-1.85 for C

228 dolphins are long-lived mammals that develop comorbidities of aging similar to humans, we analyzed da

229 ontribute to nonpulmonary manifestations and comorbidities of CF.

230 The comorbidities of HS include metabolic and cardiovascular

231 Depression is one of the most common comorbidities of many chronic medical diseases including

232 n obligate link between inflammation and the comorbidities of obesity.

233 An important comorbidity of chronic inflammation is anemia, which may

234 r previously observed sex differences in the comorbidity of major depression and cardiovascular disea

235 mic dysregulation has been implicated in the comorbidity of major psychiatric disorders and cardiovas

236 Both of these comorbidities often coexist and are independently associ

237 ient demographics, clinical characteristics, comorbidities, or medication use, and show the first mec

238 No difference in sex, performance status, comorbidity, or body mass index was found.

239 y to receive LT (highest vs. lowest level of comorbidity: OR, 0.94; 95% CI, 0.91-0.97).

240 , 1.53; P < 0.001); sight-threatening ocular comorbidity other than age-related macular degeneration

241 ny factors are not modifiable (e.g., patient comorbidity), other factors are potentially correctable

242 Patient demographics, comorbidities, preoperative laboratory results, and surg

243 Demographics, baseline comorbidities, presenting vital signs, and test results

244 Comorbidities prevalent in the endophthalmitis populatio

245 in 36 prespecified subgroups defined by age, comorbidity, previous symptom duration, and symptom seve

246 patients with a major potentially modifiable comorbidity (propensity weighted and matched effective s

247 regressions, adjusted for sociodemographics, comorbidity, psychiatric diagnoses, and self-harm.

248 fering one possible explanation for the high comorbidity rate of the two disorders.

249 Despite having high comorbidity rates and shortened life expectancy, patient

250 Age and underlying comorbidities rather than immunosuppression intensity-re

251 tion of hospitalization and other associated comorbidities related to pericardial access.

252 of individuals at risk of developing disease comorbidities represents an important task in tackling t

253 severe presbycusis without environmental or comorbidity risk factors and studied multiplex family ag

254 ients at higher risk (Charlson/Deyo Combined Comorbidity score >=2).

255 Charlson/Deyo Combined Comorbidity score analysis showed decreasing overall sur

256 0.76 [0.64-0.91]; p=0.006), and those with a comorbidity score greater than 0 (HR 0.74 [95% CI 0.59-0

257 ion, planned length of therapy, and Charlson comorbidity score.

258 patients who have another common age-related comorbidity, senile systemic amyloidosis, a nongenetic d

259 mab or aflibercept) due to either AMD or DME comorbidity, showed a significant reduction of RGC axon

260 patient demographics, year of consultation, comorbidities, smoking status, recent hospitalizations,

261 s when stratified according to age, sex, and comorbidity status, and inclusion period.

262 Comorbidities such as anemia or hypertension and physiol

263 While comorbidities such as classically syndromic presentation

264 Comorbidities such as diabetes and chronic obstructive p

265 h functional pancreas graft had at least one comorbidity, such as hypertension, hyperlipidemia, or co

266 potential risk factors of suicide (sex, age, comorbidity, surgery type, surgical approach, calendar y

267 parameters included patient characteristics, comorbidities, symptom type and duration, oxygen saturat

268 ent rates after RDN in patients with various comorbidities, testing the hypothesis that RDN is effect

269 %), and patients with persistent AF had more comorbidities than patients with paroxysmal AF.

270 Key extrahepatic comorbidities that are influenced by NAFLD are type 2 di

271 Systemic comorbidities that increased the risk of EE in candidemi

272 use but do not include patient diagnoses and comorbidities that may also affect utilization.

273 essed immune system and high-risk underlying comorbidities, the injurious effect of COVID-19 on the l

274 All patients had clinically significant comorbidities, the most common being hypertension, chron

275 Because many children have prearrest comorbidities, the P-COSCA also includes documentation o

276 Coinciding with other chronic comorbidities, the prevalence of periodontal disease inc

277 ts of mood state, medication, and other mood comorbidities, these findings serve as evidence of alter

278 These patients had higher rates of medical comorbidities, transfer from outside hospital, emergency

279 nia was associated (P<0.05) with respiratory comorbidity, tumor site, and neoadjuvant chemoradiation.

280 vs never smoked: 1.60, 1.03-2.47), number of comorbidities (two vs none: 4.50, 1.33-15.28), Eastern C

281 ong minorities, adjustment for age, sex, and comorbidities underpredicted all-cause hospitalization b

282 C15:0's direct role in attenuating multiple comorbidities using relevant physiological mechanisms at

283 In summary, prediction of T2D comorbidities utilizing Danish registers led to consiste

284 Prevalences of comorbidities, ventilator dependence, and severity of ac

285 1.53]; P<0.001 for both), although no single comorbidity was associated with a >50% rate of surveilla

286 h care costs among patients with CKD without comorbidities were 31% higher than among patients withou

287 Comorbidities were lower in white patients but did not f

288 Comorbidities were more common in Brazilians admitted to

289 Comorbidities were more prevalent among women and sexual

290 ower oxygen saturation, viral detection, and comorbidities were negatively associated with Pn-IST car

291 At the time of PPV, substantial comorbidities were noted, including corneal trauma (20%)

292 Comorbidities were present in 28%, including asthma and

293 Three or more comorbidities were present in 55% of patients, with hype

294 Median age and frequency of comorbidities were similar, but 55% (24/43) were admitte

295 Patients with high comorbidity were less likely to receive LT (highest vs.

296 ale, being of nonwhite ethnicity, and having comorbidities) were associated with higher hospitalizati

297 -year alcohol use disorder had a psychiatric comorbidity, while only one-third of heterosexual indivi

298 we report a 13-year-old child with multiple comorbidities who acquired COVID-19 5 years post-RT in t

299 ociated with the treatment of HIV-associated comorbidities with 92% mean accuracy was realized using

300 Approximately half of the patients had comorbidities, with diseases affecting the immune system